Opinion
New analysis reveals a growing interest in psilocybin that outpaces previous frontrunners MDMA and LSD.
A recent study used a battery of tests to determine what happens to creativity under a low-to-medium dose of psychedelics.
The founder of Blossom breaks apart a recent study on the process of synthesizing MDMA in this monthly column.
It’s time for psychotherapists to study the shamanic approach to plant medicine alongside their clinical applications and molecular structures.
I came close to getting arrested as a college student for selling acid at a Grateful Dead show, which would have changed my life irrevocably.
As MAPS and Vine Ventures pioneer a $70 million social impact funding vehicle for MDMA-assisted psychotherapy, it’s unclear how it will be received by funders accustomed to traditional venture capital investment models.
Floris Wolswijk, the founder of Blossom, breaks apart a recent study about the mental health benefits of microdosing in this monthly column.
We all should ask what we can do to help ensure that psychedelic therapy is safe and ethical and how we should respond when accusations of abuse are brought to light.
As we face an increasingly destabilized world, can we fuse scientific understanding with indigenous people’s deep instinct of reciprocity?
Speaking to a mainstream American audience about psychedelic therapy revealed their central concerns, along with an eagerness to learn more.
